Olaparib significantly suppressed RAD51C‐deficient tumour growth in a xenograft model.49 In addition, RAD51C promoter methylation was demonstrated to be associated with PARP inhibitor response in a PDX model.19 This evidence concerns the gene PARP1 and neoplasm.